Executive Summary

The PD-1 and PD-L1 product landscape is best understood as a mature oncology platform rather than a single-product market. Pembrolizumab remains the dominant commercial product, nivolumab remains the major second PD-1 franchise, and PD-L1 products such as durvalumab and atezolizumab continue to anchor clinically meaningful segments of lung, bladder, hepatobiliary, and other oncology use.

The class has shifted from advanced-disease immunotherapy toward broader treatment architecture. Current strategic value is increasingly tied to earlier-line use, perioperative regimens, biomarker-defined populations, fixed-dose or subcutaneous lifecycle extensions, and rational combinations with chemotherapy, anti-CTLA-4 therapy, targeted therapy, antibody-drug conjugates, and radiotherapy.

For economic analysis, the article separates annual worldwide manufacturer net sales from partial-period run-rate context and from U.S. public-payer spending. Solid revenue lines in the figure represent annual worldwide manufacturer net sales, while open markers represent annualized quarterly run-rates. This visual convention avoids implying that Q4 2025 or Q1 2026 markers are completed annual revenue values.

Mechanistic and Clinical Frame

PD-1 and PD-L1 inhibitors target the same immune checkpoint axis but bind different sides of the receptor-ligand interaction: PD-1 antibodies bind programmed death receptor-1 on immune cells, while PD-L1 antibodies bind programmed death ligand-1 on tumor cells or immune cells in the tumor microenvironment. Both approaches are used to restore antitumor immune activity, although product labels, tumor settings, combination partners, and safety language differ by molecule and indication.12345

The clinical utility of the class is broad but not uniform. PD-1 and PD-L1 agents are used across multiple tumor types, yet treatment selection depends on indication-specific factors such as line of therapy, disease stage, histology, prior therapy, PD-L1 testing requirements, mismatch repair or microsatellite instability status, tumor mutational biology, and whether the regimen is monotherapy or combination therapy.234567

Safety remains class-defining. U.S. prescribing information for checkpoint inhibitors includes warnings for immune-mediated adverse reactions, infusion-related or administration-related reactions, and other product-specific risks; these risks are central to clinical positioning because the drugs are often used in patients with advanced cancer, multimodal therapy exposure, or curative-intent perioperative regimens.234589

Approved Product Landscape

The U.S. PD-1 segment includes large multi-indication products such as pembrolizumab and nivolumab, narrower or more tumor-specific entrants such as cemiplimab, dostarlimab, retifanlimab, toripalimab, and penpulimab, and lifecycle extensions through subcutaneous pembrolizumab and subcutaneous nivolumab combinations with hyaluronidase.121031176121314

The U.S. PD-L1 segment is smaller but clinically important. Atezolizumab, durvalumab, and avelumab represent the established PD-L1 franchises, while cosibelimab adds a more recent PD-L1 approval in cutaneous squamous cell carcinoma.458159

Market Structure

Commercially, the class is highly concentrated. Pembrolizumab is the dominant worldwide PD-1 product, with Merck reporting Keytruda sales of approximately $29.5 billion in 2024 and public financial reporting indicating approximately $31.7 billion in 2025. In the accompanying figure, Keytruda remains the clear scale outlier, and the open 2026 marker is shown only as a Q1 annualized run-rate rather than a completed annual result.161718

Nivolumab remains the second major global PD-1 franchise. The figure presents Opdivo as a materially smaller but still durable PD-1 franchise, with a 2025 value shown at approximately $10.3 billion using reported quarterly values and disclosed Opdivo Qvantig contribution where available. The open 2026 marker is again a Q1 annualized run-rate, not a full-year actual.19202111

PD-L1 products occupy a different commercial profile. Durvalumab and atezolizumab remain clinically important, but the figure shows that neither has matched the commercial scale of Keytruda or Opdivo. Imfinzi is shown through a rounded 2025 annual value of approximately $6.0 billion, while Tecentriq is shown as an annual line through 2024 plus a separate open Q4 2025 annualized marker because the plot treats that point as partial-period context rather than full-year 2025 product revenue.2223242554

The most important 2026 strategic dynamic is not simply the number of approved products. It is the interaction among label breadth, route-of-administration lifecycle management, patent and exclusivity timing, earlier-stage disease penetration, biomarker requirements, and combination development.1619101123

Spending and Revenue Data

Publicly available economic data support two complementary views of the PD-1/PD-L1 market. For the United States, CMS Medicare Part B Drug Spending by Drug provides a product-level public-payer series for many clinician-administered oncology drugs, including major PD-1 and PD-L1 products billed under Medicare Part B. This dataset is useful for trend plotting, but it is a Medicare Part B spending measure, not a total U.S. all-payer market estimate.26

Click to enlarge

The figure above focuses on worldwide manufacturer net sales, not U.S. payer spending. Solid lines represent annual manufacturer-reported product sales through the latest annual value used in the figure. Open markers represent annualized quarterly run-rates: Tecentriq is shown with a Q4 2025 annualized marker, while Keytruda and Opdivo are shown with Q1 2026 annualized markers. These open markers are directional context and should not be interpreted as full-year actual revenue.1617181920212325

The main commercial message is concentration. Keytruda is the dominant franchise by a wide margin, Opdivo remains the second major PD-1 product, and the PD-L1 products shown in the figure remain smaller despite meaningful clinical use. The figure is therefore best read as a scale and trajectory graphic, not as a complete health-system spending estimate.17202325

For worldwide trends, company-reported product net sales remain the most reproducible public source. Merck reports Keytruda sales, Bristol Myers Squibb reports Opdivo sales, AstraZeneca reports Imfinzi sales, and Roche reports Tecentriq sales. These data are manufacturer revenue rather than gross health-system expenditure, but they provide a transparent public time series for global product scale.16192224

Combining CMS Medicare Part B spending and worldwide company net sales into a single y-axis should be avoided unless the visual explicitly states that the measures are not equivalent. CMS spending reflects a U.S. public-payer program and payment construct, while company net sales reflect manufacturer revenue after discounts, rebates, returns, and other accounting adjustments defined by the reporting company.2616192224

Lifecycle Management

Subcutaneous administration is now a central lifecycle-management theme for the class. FDA approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in December 2024 for most previously approved adult solid-tumor Opdivo indications, and FDA approved pembrolizumab and berahyaluronidase alfa-pmph for subcutaneous injection in September 2025 for use across many adult solid-tumor Keytruda settings.1110

The strategic rationale for subcutaneous formulations is broader than patient convenience. These products may support clinic throughput, reduce infusion-chair dependence, extend franchise durability, and partially defend market position as future competition evolves. The clinical and regulatory basis remains product-specific, and each formulation must be evaluated against its own label, study package, dosing schedule, and approved indications.111032

Lifecycle management is also occurring through regimen architecture. PD-1 and PD-L1 products are increasingly embedded in combination regimens, earlier-stage settings, and perioperative treatment approaches, which can increase treatment duration, move therapy closer to curative-intent disease, and complicate attribution of product value across combination partners.2354

Clinical Development Direction

The development frontier is not simply another monotherapy checkpoint inhibitor. In many common tumor types, the next wave of value is likely to come from combinations, sequencing strategies, perioperative regimens, and biomarker-defined subsets where checkpoint blockade can be paired with agents that increase antigen release, remodel the tumor microenvironment, or target resistant disease biology.235427

Earlier-stage and perioperative use create a different risk-benefit and evidence problem than metastatic use. In curative-intent settings, sponsors must balance event-free survival, disease-free survival, overall survival maturity, surgical feasibility, pathologic response, immune-related toxicity, and the acceptability of exposing patients to systemic immunotherapy before or after definitive local therapy.23527

Biomarker strategy remains uneven across the class. Some indications use PD-L1 expression thresholds, some rely on MSI-H or dMMR status, some use histology or disease stage without a companion diagnostic requirement, and some combine immunotherapy with chemotherapy or targeted therapy in ways that reduce the apparent dependence on PD-L1 enrichment.23456

Regulatory and Access Outlook

From a regulatory perspective, the U.S. product universe is now broad enough that a new PD-1 or PD-L1 antibody needs a differentiated use case rather than a generic checkpoint-inhibitor premise. Differentiation may come from a rare tumor, regional evidence bridge, biomarker-defined population, route of administration, combination partner, or evidence in a setting where established products do not yet have a strong label position.12345131415

Access pressure is likely to increase because the class is both clinically important and commercially large. Public spending datasets, payer policies, Medicare price-negotiation dynamics, and biosimilar or follow-on competition will matter increasingly as major franchises approach later lifecycle stages. This is especially relevant for Keytruda, where public reporting has identified future Medicare price-setting and patent-timing pressure as major strategic issues. The exact timing and magnitude of access pressure will remain product-specific and jurisdiction-specific.2616171928

For portfolio strategy, the practical implication is that the checkpoint-inhibitor category should be treated as infrastructure for oncology development rather than as an undifferentiated drug class. Product value will depend on how the antibody is embedded into a tumor-specific regimen, how convincingly the evidence supports incremental benefit, and whether the commercial model can withstand price, patent, and administrative-site-of-care pressure.23541619